"We think this means Amgen's probability of winning its patent infringement case has increased dramatically," said Mark Schoenebaum, an analyst at Bear Stearns, in a research report.Monsters and Critics noted: documents released last week indicate it`s a pegylated version of an EPO product. [read post]